Mangoceuticals, Inc. (MGRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MGRX SEC filings page.
Mangoceuticals, Inc. (MGRX) reported $315K in revenue over the twelve months to Jun 30, 2026, down 38.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Mangoceuticals has shrinking sales, widening operating losses, and a balance sheet financed more by capital than by operating cash generation.
Gross margin compressed from61.7% to54.9% while operating losses widened sharply by FY2025, indicating weaker economics beyond the sales decline. Operating cash outflow of$5.9M alongside$7.3M of financing inflow shows that external funding supported the period rather than internally generated cash.
The company is balance-sheet-heavy relative to its sales: FY2025 assets were
Liquidity improved as the current ratio moved from 0.1x in FY2024 to 1.7x in FY2025. Current liabilities fell to
Financial Health Signals
Mangoceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Mangoceuticals, Inc. scores -1.03, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($9.1M) relative to total liabilities ($891K). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Mangoceuticals, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Mangoceuticals, Inc. reported a net loss of $20.6M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Mangoceuticals, Inc. reported an operating loss of $18.0M against $104K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Mangoceuticals, Inc. generated $69K in revenue in Q2 2026. This represents a decrease of 59.1% from the same quarter a year earlier. Against the prior quarter it is up 1.3%.
Mangoceuticals, Inc.'s EBITDA was -$753K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. Against the prior quarter it is up 73.6%.
Mangoceuticals, Inc. reported -$1.3M in net income in Q2 2026. This represents an increase of 75.8% from the same quarter a year earlier. Against the prior quarter it is up 61.4%.
Mangoceuticals, Inc. earned -$0.09 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 59.1%.
Cash & Balance Sheet
Mangoceuticals, Inc. held $229K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Mangoceuticals, Inc.'s gross margin was 64.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 10.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 21.6 percentage points.
Mangoceuticals, Inc.'s ROE was -10.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 17.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 14.8 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
None of these metrics is reported for Q2 2026.
MGRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $69K-59.1% | $68K-37.9% | $94K-10.3% | $84K-36.8% | $168K+3.0% | $109K-48.9% | $105K-56.9% | $133K-45.6% |
| Cost of Revenue | $10K-44.5% | $8K-66.8% | $9K-60.1% | $2K-89.0% | $19K-36.6% | $25K+19.0% | $21K-60.0% | $22K-58.8% |
| Gross Profit | $44K-50.8% | $29K-53.3% | $47K-40.7% | $51K-38.4% | $90K+28.9% | $62K-57.9% | $80K-43.8% | $83K-42.8% |
| SG&A Expenses | $256K-79.4% | $1.1M-31.7% | $657K-23.1% | $311K-40.6% | $1.2M+46.4% | $1.5M+99.8% | $854K-58.9% | $524K-3.9% |
| Operating Income | -$1.0M+80.4% | -$3.1M+31.7% | -$645K | -$7.5M-329.0% | -$5.3M-142.9% | -$4.6M | N/A | -$1.8M+2.3% |
| EBITDA | -$753K | -$2.8M+37.7% | N/A | N/A | N/A | -$4.6M | N/A | -$1.8M+1.8% |
| Interest Expense | N/A | N/A | $20K | $76K | $22K | -$14K | N/A | N/A |
| Net Income | -$1.3M+75.8% | -$3.4M+29.7% | -$2.8M | -$7.6M-281.1% | -$5.4M-126.5% | -$4.8M | N/A | -$2.0M-11.1% |
| EPS (Basic) | -$0.09+84.2% | -$0.22+80.4% | -$0.01+99.0% | -$0.69+39.5% | -$0.57+58.4% | -$1.12+25.3% | -$1.01+46.8% | -$1.14+32.9% |
| EPS (Diluted) | -$0.09 | -$0.22 | -$0.01 | -$0.69 | -$0.57 | -$1.12 | -$1.01 | -$1.14 |
| Diluted Shares (Avg) | 17M | 16M | N/A | 12M | 10M | 5M | N/A | 2M |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
MGRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $14.2M-32.0% | $14.4M-33.6% | $16.1M+4.7% | $16.5M+11.8% | $20.8M+36.8% | $21.8M+7116.5% | $15.4M+1362.8% | $14.8M+827.1% |
| Current Assets | $246K+108.3% | $212K+20.3% | $1.5M+1947.0% | $598K+474.8% | $118K-77.2% | $177K+96.7% | $76K-91.0% | $104K-92.2% |
| Cash & Equivalents | $229K+126.4% | $175K+128.2% | $1.5M+2434.1% | $481K+551.2% | $101K-79.4% | $76K+399.8% | $59K-92.1% | $74K-94.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $13K-38.8% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.6M+3.0% | $975K-35.2% | $891K-37.5% | $804K-42.7% | $1.6M+13.7% | $1.5M+19.3% | $1.4M+416.4% | $1.4M+483.2% |
| Current Liabilities | $1.4M-12.7% | $738K-50.9% | $891K-37.5% | $804K-42.2% | $1.6M+16.2% | $1.5M+24.0% | $1.4M+575.3% | $1.4M+774.1% |
| Non-Current Liabilities | $251K | $237K | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $12K-85.1% |
| Total Equity | $12.5M-34.9% | $13.5M-33.5% | $15.2M+9.0% | $15.7M+17.5% | $19.2M+39.1% | $20.3M+2213.0% | $13.9M+1700.1% | $13.4M+888.3% |
| Retained Earnings | -$45.4M-43.3% | -$44.1M-69.8% | -$40.6M-103.2% | -$37.9M-110.6% | -$31.6M-98.0% | -$25.9M-90.8% | -$20.0M-78.2% | -$18.0M-107.7% |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
MGRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$261K+79.3% | -$1.3M+42.4% | -$1.1M+4.6% | -$1.2M-6.5% | -$1.3M+20.3% | -$2.3M-129.5% | -$1.1M+33.5% | -$1.2M+31.9% |
| Depreciation & Amortization | $280K | $277K+110726.0% | N/A | N/A | N/A | $250-96.0% | $255-95.9% | $3K-72.4% |
| Stock-Based Compensation | N/A | $1.1M+2038.4% | N/A | N/A | N/A | $51K+34.3% | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Financing Cash Flow | N/A | N/A | $2.1M+85.6% | $1.6M+116.2% | $1.3M-35.6% | $2.3M+754.2% | $1.1M-6.5% | $750K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
MGRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.3%+10.8pp | 42.7%-14.0pp | 50.3%-25.8pp | 60.4%-1.6pp | 53.5%+10.7pp | 56.8%-12.1pp | 76.1%+17.8pp | 62.0%+3.0pp |
| Operating Margin | -1502.5% | -4606.8% | -683.1% | -8953.4% | -3134.0% | -4186.8% | N/A | -1318.2% |
| Net Margin | -1909.1% | -5014.7% | -2935.1% | -9042.8% | -3221.6% | -4427.4% | N/A | -1499.0% |
| Return on Equity | -10.5%+17.7pp | -25.3%-1.4pp | -18.2% | -48.4%-33.5pp | -28.1%-10.8pp | -23.9% | N/A | -14.9%+117.9pp |
| Return on Assets | -9.3%+16.7pp | -23.5%-1.3pp | -17.2% | -46.1%-32.6pp | -26.0%-10.3pp | -22.3% | N/A | -13.5%+99.3pp |
| Current Ratio | 0.18+0.1x | 0.29+0.2x | 1.74+1.7x | 0.74+0.7x | 0.07-0.3x | 0.120.0x | 0.05-3.9x | 0.07-8.4x |
| Debt-to-Equity | 0.130.0x | 0.070.0x | 0.060.0x | 0.05-0.1x | 0.080.0x | 0.07 | 0.10-0.3x | 0.10-0.1x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.01-0.7x | 0.01-0.2x | 0.01-0.1x |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Mangoceuticals, Inc. MGRX | FY2025 | $456K | -$20.6M | N/A | $9.1M | — |
| Zhongchao Inc. ZCMD | FY2025 | $11.4M | -$6.3M | -55.5% | $7.1M | 33/100 |
| DarioHealth Corp. DRIO | FY2025 | $22.4M | -$41.7M | N/A | $56.8M | 54/100 |
| Healthcare Triangle, Inc. HCTI | FY2025 | $13.9M | -$9.5M | -68.2% | $7.1M | 30/100 |
| VSEE HEALTH INC VSEE | FY2025 | $14.6M | -$14.7M | N/A | $4.7M | — |
Where Mangoceuticals, Inc. Ranks
Frequently Asked Questions
What is Mangoceuticals, Inc.'s annual revenue?
Mangoceuticals, Inc. (MGRX) reported $456K in total revenue for fiscal year 2025. This represents a -26.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Mangoceuticals, Inc.'s revenue growing?
Mangoceuticals, Inc. (MGRX) revenue declined by 26.0% year-over-year, from $616K to $456K in fiscal year 2025.
Is Mangoceuticals, Inc. profitable?
No, Mangoceuticals, Inc. (MGRX) reported a net income of -$20.6M in fiscal year 2025.
What is Mangoceuticals, Inc.'s EBITDA?
Mangoceuticals, Inc. (MGRX) had EBITDA of -$16.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Mangoceuticals, Inc.'s gross margin?
Mangoceuticals, Inc. (MGRX) had a gross margin of 54.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Mangoceuticals, Inc.'s return on equity (ROE)?
Mangoceuticals, Inc. (MGRX) has a return on equity of -135.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Mangoceuticals, Inc.'s operating cash flow?
Mangoceuticals, Inc. (MGRX) recorded an outflow of $5.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Mangoceuticals, Inc.'s total assets?
Mangoceuticals, Inc. (MGRX) had $16.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Mangoceuticals, Inc.'s current ratio?
Mangoceuticals, Inc. (MGRX) had a current ratio of 1.74 as of fiscal year 2025, which is generally considered healthy.
What is Mangoceuticals, Inc.'s debt-to-equity ratio?
Mangoceuticals, Inc. (MGRX) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mangoceuticals, Inc.'s return on assets (ROA)?
Mangoceuticals, Inc. (MGRX) had a return on assets of -128.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Mangoceuticals, Inc.'s P/E ratio?
Mangoceuticals, Inc. (MGRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $9.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Mangoceuticals, Inc.'s price-to-sales ratio?
Mangoceuticals, Inc. (MGRX) trades at 28.9x sales, its market capitalization divided by revenue of $315K revenue, trailing 12 months to June 30, 2026. The market capitalization is $9.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Mangoceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Mangoceuticals, Inc. (MGRX) held $1.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.9M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Mangoceuticals, Inc.'s Altman Z-Score?
Mangoceuticals, Inc. (MGRX) has an Altman Z-Score of -1.03, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Mangoceuticals, Inc.'s Piotroski F-Score?
Mangoceuticals, Inc. (MGRX) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mangoceuticals, Inc.'s earnings high quality?
Mangoceuticals, Inc. (MGRX) reported a net loss of $20.6M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Mangoceuticals, Inc. cover its interest payments?
Mangoceuticals, Inc. (MGRX) reported an operating loss of $18.0M against $104K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.